Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.33 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.33 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.33 |
| ▸ | MGAM | O43451 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | SI | P14410 | 1/20 | 0.31 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.30 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11255718 | 1.00 | ALDH1A1 (0.42) | ALDH1A1KEAP1NFE2L2HCAR2MGAM | |
| SCHEMBL294152 | 1.00 | ALDH1A1 (0.42) | ALDH1A1KEAP1NFE2L2HCAR2MGAM | |
| SCHEMBL25246818 | 0.92 | ALDH1A1 (0.48) | ALDH1A1KEAP1NFE2L2HCAR2MGAM | |
| SCHEMBL13931043 | 0.82 | ALDH1A1 (0.40) | ALDH1A1KEAP1NFE2L2HCAR2 | |
| SCHEMBL18070830 | 0.82 | ALDH1A1 (0.40) | ALDH1A1KEAP1NFE2L2HCAR2EGLN1 | |
| SCHEMBL2726802 | 0.82 | PTGS1 (0.41) | ALDH1A1KEAP1NFE2L2HCAR2EGLN1 | |
| SCHEMBL9068083 | 0.81 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL19526556 | 0.80 | ALDH1A1 (0.39) | ALDH1A1KEAP1NFE2L2HCAR2EGLN1 | |
| SCHEMBL16656584 | 0.80 | ALDH1A1 (0.39) | ALDH1A1KEAP1NFE2L2HCAR2 | |
| SCHEMBL27485285 | 0.80 | PTGS1 (0.40) | ALDH1A1KEAP1NFE2L2HCAR2EGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6011169-A | Process for producing optically active cyclopropanecaboxylic acid esters | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2000-01-04 | — | — | US | claimed |
| US-4328363-A | Manufacture of gamma halogen substituted adducts | MOBIL OIL CORPORATION (US) | 1982-05-04 | — | — | US | claimed |
| CN-107954811-A | Transforming oxygenated organic compound is the method for C_4 hydrocarbon class compound | 中国石油化工股份有限公司 | 2018-04-24 | — | — | CN | disclosed |
| CN-103958533-B | Optically active bisoxazoline compound, asymmetric catalyst, and method for producing optically active cyclopropane compound using same | SUMITOMO CHEMICAL CO.,LTD. (JP) | 2016-02-10 | — | — | CN | disclosed |
| EP-1783111-B1 | METHOD FOR PRODUCING OPTICALLY ACTIVE CYCLOPROPANECARBOXYLATE COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2015-04-08 | — | — | EP | disclosed |
| CN-104080864-A | Inkjet ink and inkjet recording device | RICOH CO LTD | 2014-10-01 | — | — | CN | disclosed |
| EP-2781522-A1 | OPTICALLY ACTIVE BISOXAZOLINE COMPOUND, ASYMMETRIC CATALYST, AND METHOD FOR PRODUCING OPTICALLY ACTIVE CYCLOPROPANE COMPOUND USING SAID CATALYST | Sumitomo Chemical Company, Limited (JP) | 2014-09-24 | — | — | EP | disclosed |
| CN-103958533-A | Optically active bis-oxazoline compound, asymmetric catalyst, and method for producing optically active cyclopropane compound using same | SUMITOMO CHEMICAL CO | 2014-07-30 | — | — | CN | disclosed |
| EP-1607136-B1 | OPTICALLY ACTIVE COPPER CATALYST COMPOSITION | SUMITOMO CHEMICAL CO (JP) | 2012-05-23 | — | — | EP | disclosed |
| EP-1683783-B1 | Chiral copper complex and production processes thereof and using the same | SUMITOMO CHEMICAL CO (JP) | 2012-03-14 | — | — | EP | disclosed |
| EP-1683782-B1 | Chiral copper complex and production processes thereof and using the same | SUMITOMO CHEMICAL CO (JP) | 2012-03-14 | — | — | EP | disclosed |
| US-20010037036-A1 | Chiral copper complex catalyst composition and asymmetric production process using the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2001-11-01 | — | — | US | disclosed |
| EP-1120402-A2 | Chiral copper complex and production processes thereof and using the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2001-08-01 | — | — | EP | disclosed |
| EP-1120401-A2 | Chiral copper complex catalyst composition and asymmetric production process using the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2001-08-01 | — | — | EP | disclosed |
| US-6072081-A | Optically active bisoxazoline compounds, production and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2000-06-06 | — | — | US | disclosed |
| US-6011169-A | Process for producing optically active cyclopropanecaboxylic acid esters | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2000-01-04 | — | — | US | disclosed |
| EP-0895992-A2 | Copper complexes of optically active bisoxazolines as enantioselective catalysts in cyclopropanation reactions | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1999-02-10 | — | — | EP | disclosed |
| EP-0891965-A1 | Process for producing optically active cyclopropanecarboxylic acid esters | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 1999-01-20 | — | — | EP | disclosed |
| CN-1205326-A | Process for producing opitically active cyclopropanecaboxylic acid esters | SUMITOMO CHEMICAL CO (JP) | 1999-01-20 | — | — | CN | disclosed |
| US-4328363-A | Manufacture of gamma halogen substituted adducts | MOBIL OIL CORPORATION (US) | 1982-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010037036-A1 | Chiral copper complex catalyst composition and asymmetric production process using the same | AP1M1, UBA3, AP1S1 | ALDH1A1 254/4885KEAP1 886/4885NFE2L2 676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.